Physician

Luke T Nordquist, M.D.

According to 2025 Medicare claims, Luke Nordquist, M.D. (NPI: 1538149414) practices medical oncology in the Omaha, NE-IA market, with the plurality of this provider's patient population coming from Douglas, NE. This provider's primary affiliated billing organization is UROLOGY CANCER CENTER PC (NPI: 1619279312; TIN: 273930084) and primary practice location at 68130-5606. Nordquist is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), Main Street Rural Health Maple ACO LLC (ACO ID: A5401), Collaborative ACO 30, LLC (ACO ID: A5483), CoreHealth Alliance LLC (ACO ID: A5645), and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Nordquist's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 655 traditional Medicare patients, billed 88,294 HCPCS/CPT codes, and received $3,419,715 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,520 prescription claims across 194 beneficiaries totaling $11,391,308 in drug costs, led by Xtandi (Enzalutamide). Open Payments data shows 334 records totaling $3,797,468. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,850,001 to $3,419,715. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,014,417 to $11,391,308. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	395	132,338	$2,850,001
2016	460	106,170	$3,090,049
2017	526	110,605	$2,704,109
2018	543	81,808	$2,153,930
2019	580	98,158	$2,620,465
2020	572	115,504	$3,050,227
2021	576	117,148	$2,521,830
2022	617	110,033	$4,850,799
2023	636	99,398	$5,070,241
2024	655	88,294	$3,419,715

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	107	817	$3,014,417
2016	127	946	$3,976,164
2017	149	1,132	$6,140,270
2018	166	1,207	$7,560,318
2019	181	1,418	$8,504,834
2020	185	1,354	$8,514,950
2021	191	1,401	$9,235,262
2022	201	1,592	$12,554,687
2023	191	1,602	$12,332,438
2024	194	1,520	$11,391,308

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	342	923	$89
84403	Testosterone (hormone) level, total	514	1,446	$25
84153	Psa (prostate specific antigen) measurement, total	534	1,570	$18
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	440	831	$11
36415	Insertion of needle into vein for collection of blood sample	581	1,819	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	540	16,200	$7,330,898
Nubeqa	Darolutamide	167	5,010	$2,200,926
Erleada	Apalutamide	83	2,490	$1,165,591
Abiraterone Acetate	Abiraterone Acetate	249	7,470	$180,613
Orgovyx	Relugolix	68	2,040	$172,662

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$727	Telix Pharmaceuticals
Research Payments	Reported research-related payment or transfer-of-value amount.	311	$3,796,740	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Luke T. Nordquist, M.D.?

Tedicare shows public-source Medicare data for Luke T. Nordquist, M.D. (NPI 1538149414), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Luke T. Nordquist, M.D. have ACO affiliation data?

Luke T. Nordquist, M.D. is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), Main Street Rural Health Maple ACO LLC (MSSP, ACO ID A5401), Collaborative ACO 30, LLC (MSSP, ACO ID A5483), CoreHealth Alliance LLC (MSSP, ACO ID A5645), and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Luke T. Nordquist, M.D.?

Luke T. Nordquist, M.D. is linked to UROLOGY CANCER CENTER PC (billing NPI 1619279312) in the available physician profile data.

Does Luke T. Nordquist, M.D. have Open Payments data?

Luke T. Nordquist, M.D. has 334 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.